[ASAP] Comment on: “Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy”

Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00903

Source: Molecular Pharmaceutics - December 28, 2022 Category: Drugs & Pharmacology Authors: Tian Tian Source Type: research